1-Jahres-Chart
5-Tage-Chart
| Realtime | Geld | Brief | Zeit |
|---|---|---|---|
| 14,500 | 16,500 | 17:15 |
- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| Mo | ASCENTAGE PHARMA GROUP INTERNATIONAL - 6-K, Report of foreign issuer | 1 | SEC Filings | ||
| ASCENTAGE PHARMA GROUP INTERNATIONAL ADR Aktie jetzt für 0€ handeln | |||||
| Mo | Wall Street Analysts Predict a 160.09% Upside in Ascentage Pharma Group International - Unsponsored ADR (AAPG): Here's What You Should Know | 1 | Zacks | ||
| Mo | ASCENTAGE PHARMA GROUP INTERNATIONAL: Ascentage Pharma Chairman and CEO Dr. Dajun Yang Named to The Medicine Maker Power List 2026 | 1 | GlobeNewswire (USA) | ||
| 20.07. | ASCENTAGE Plans ATM Offering of ADSs in US to Raise Up to USD200 million | 15 | AASTOCKS | ||
| 13.07. | ASCENTAGE PHARMA GROUP INTERNATIONAL - 6-K, Report of foreign issuer | 1 | SEC Filings | ||
| 13.07. | ASCENTAGE (06855): UPDATE ON THE FURTHER GRANT OF AWARDS UNDER THE 2021 RSU SCHEME AND THE 2022 RSU SCHEME; AND FURTHER GRANT OF OPTIONS UNDER THE POST ... | 1 | HKEx | ||
| 09.07. | How Much Upside is Left in Ascentage Pharma Group International - Unsponsored ADR (AAPG)? Wall Street Analysts Think 152.23% | 1 | Zacks | ||
| 30.06. | ASCENTAGE PHARMA GROUP INTERNATIONAL - 6-K, Report of foreign issuer | 1 | SEC Filings | ||
| 30.06. | ASCENTAGE (06855): FURTHER GRANT OF AWARDS UNDER THE 2021 RSU SCHEME AND THE 2022 RSU SCHEME; AND FURTHER GRANT OF OPTIONS UNDER THE POST IPO SHARE OPTION ... | 1 | HKEx | ||
| 15.06. | ASCENTAGE PHARMA GROUP INTERNATIONAL: Ascentage Pharma Presents Multiple Clinical Updates at EHA2026 Congress | 2 | GlobeNewswire (USA) | ||
| 15.06. | ASCENTAGE (06855): VOLUNTARY ANNOUNCEMENT - ASCENTAGE PHARMA RELEASES MULTIPLE CLINICAL UPDATES AT EHA2026 CONGRESS | 2 | HKEx | ||
| 10.06. | ASCENTAGE PHARMA GROUP INTERNATIONAL - 6-K, Report of foreign issuer | 1 | SEC Filings | ||
| 10.06. | ASCENTAGE (06855): VOLUNTARY ANNOUNCEMENT - PURCHASE OF SHARES BY THE TRUSTEE FOR THE PURPOSE OF THE 2022 RSU SCHEME | - | HKEx | ||
| 10.06. | B.Riley initiates Ascentage Pharma stock with buy, $45 target | 1 | Investing.com | ||
| 01.06. | ASCENTAGE PHARMA GROUP INTERNATIONAL - 6-K, Report of foreign issuer | 1 | SEC Filings | ||
| 01.06. | ASCENTAGE PHARMA GROUP INTERNATIONAL: Ascentage Pharma Presents Updated Clinical Data for Olverembatinib as Second-Line Therapy in CML-CP at ASCO 2026 | 1 | GlobeNewswire (USA) | ||
| 01.06. | ASCENTAGE PHARMA GROUP INTERNATIONAL: Ascentage Pharma Presents Its First Dataset on MDM2-p53 Inhibitor Alrizomadlin (APG-115) in Pediatric Solid Tumors at ASCO 2026 | 1 | GlobeNewswire (USA) | ||
| 01.06. | ASCENTAGE PHARMA GROUP INTERNATIONAL: Ascentage Pharma Presents Data on Olverembatinib in CML-LBP and Ph+ BCP-ALL at ASCO 2026 | 2 | GlobeNewswire (USA) | ||
| 27.05. | ASCENTAGE-B (06855): VOLUNTARY ANNOUNCEMENT - PURCHASE OF SHARES BY THE TRUSTEE FOR THE PURPOSE OF THE 2022 RSU SCHEME | - | HKEx | ||
| 27.05. | ASCENTAGE-B (06855): DIS-APPLICATION OF RULES 18A.09 TO 18A.11 OF THE LISTING RULES AND REMOVAL OF STOCK MARKER | - | HKEx |
1 2 3 4 Weiter >>
73 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| CARIS LIFE SCIENCES | 13,500 | -1,46 % | Caris Life Sciences: Revolutionäre Krebsfrüherkennung mit KI und Big Data | Caris Life Sciences ist ein hochinnovatives Unternehmen im Bereich Präzisionsmedizin und Krebsdiagnostik. Während viele Investoren bei Biotech sofort an riskante Frühphasen-Firmen denken, die noch kein... ► Artikel lesen | |
| AKTIS ONCOLOGY | 22,690 | +1,34 % | Aktis Oncology Inc.: Aktis Oncology Reports First-in-Human Clinical Imaging and Dosimetry Data for AKY-2519 Demonstrating Robust Tumor Uptake and Limited Normal Tissue Exposures in Patients with B7-H3 Expressing Tumors | Data to be presented across two posters at the 2026 American Society of Clinical Oncology (ASCO) Annual MeetingCombined results evaluating AKY-2519 across several B7-H3 expressing tumor types, including... ► Artikel lesen | |
| PARABILIS MEDICINES | 32,050 | +0,28 % | Parabilis Medicines, Inc.: Parabilis Medicines Announces Closing of Upsized Initial Public Offering, Including Full Exercise of Underwriters' Option to Purchase Additional Shares | CAMBRIDGE, Mass., June 11, 2026 (GLOBE NEWSWIRE) -- Parabilis Medicines, Inc. (Nasdaq: PBLS) ("Parabilis"), a clinical-stage biopharmaceutical company built to develop transformative medicines addressing... ► Artikel lesen | |
| APIMEDS PHARMACEUTICALS US | 6,460 | -18,64 % | Apimeds Pharmaceuticals US Inc. Announces Material Breach of Merger Agreement by Inscobee Inc. and Apimeds Inc.; Prepares Filing Emergency Action in Delaware Court of Chancery | MATAWAN, N.J. & SEOUL, South Korea--(BUSINESS WIRE)--MindWave Innovations Inc., a Delaware corporation and wholly owned subsidiary of Apimeds Pharmaceuticals US, Inc. ("APUS" or the "Company") (NYSE... ► Artikel lesen | |
| QIAGEN | 36,095 | -2,26 % | PTA-PVR: QIAGEN N.V.: Veröffentlichung nach § 40 Abs. 1 WpHG | DJ PTA-PVR: QIAGEN N.V.: Veröffentlichung nach § 40 Abs. 1 WpHG
Veröffentlichung gem. -- 40 Abs. 1 WpHG
QIAGEN N.V.: Veröffentlichung nach -- 40 Abs. 1 WpHG
Venlo (pta000/29.07.2026/22:05... ► Artikel lesen | |
| PRAXIS PRECISION MEDICINES | 296,75 | +0,32 % | Praxis Precision Medicines, Inc.: Praxis Precision Medicines Announces Extension Period for Relutrigine for Treatment of SCN2A and SCN8A Developmental and Epileptic Encephalopathies | FDA sets updated PDUFA date of December 27, 2026 BOSTON, June 29, 2026 (GLOBE NEWSWIRE) -- Praxis Precision Medicines, Inc. (NASDAQ: PRAX), a fully integrated, leading central nervous system (CNS)... ► Artikel lesen | |
| APOGEE THERAPEUTICS | 134,18 | -0,01 % | Laufende Fusionskontrollverfahren: AbbVie Inc., North Chicago/Illinois/USA; Erwerb von Anteilen an und alleiniger Kontrolle über die Apogee Therapeutics, Inc., San Francisco/CA/USA | Datum der Anmeldung:07.07.2026Aktenzeichen:B3-76/26Unternehmen:AbbVie Inc., North Chicago/Illinois/USA; Erwerb von Anteilen an und alleiniger Kontrolle über die Apogee Therapeutics, Inc., San Francisco/CA/USAProduktmärkte:Biotechnologie... ► Artikel lesen | |
| CLIMB BIO | 12,580 | +2,36 % | Climb Bio, Inc.: Climb Bio Announces Initial Phase 1b Data Demonstrating On-Target Clinical Activity for Budoprutug in Immune Thrombocytopenia at EHA Congress 2026 | Data demonstrate favorable safety and tolerability profile, robust B- cell depletion, and encouraging platelet responses in heavily pretreated patients with primary immune thrombocytopenia Enrollment... ► Artikel lesen | |
| ERASCA | 18,265 | +0,58 % | Erasca, Inc.: Erasca Announces Updated Preliminary Phase 1 Data and Registration-Enabling Plans for Potentially Best-in-Class Pan-RAS Molecular Glue ERAS-0015 in KRAS-Mutant Solid Tumors | At RDE of 32 mg QD, encouraging monotherapy responses with 57% uORR in 2L+ KRAS G12X pancreatic cancer in U.S. trial and median relative dose intensity of 100% Monotherapy has been generally well-tolerated... ► Artikel lesen | |
| PHATHOM PHARMACEUTICALS | 9,845 | -15,57 % | Phathom Pharmaceuticals, Inc. (PHAT) Reports Break-Even Earnings for Q2 | ||
| KINIKSA PHARMACEUTICALS | 79,64 | +0,25 % | Kiniksa Pharmaceuticals International, Plc: Kiniksa Pharmaceuticals Reports Second Quarter 2026 Financial Results and Recent Portfolio Execution | - ARCALYST (rilonacept) Q2 2026 net product revenue of $243.6 million, representing ~55% year-over-year growth -- ARCALYST 2026 expected net product revenue increased to $980 - $995 million -- KPL-387... ► Artikel lesen | |
| EVOTEC | 3,482 | +0,35 % | Keine Ende der Rallye in Sicht: Diese Biotechnologie-Aktie bietet für ihr Geld so viel wie kaum eine zweite! | © Foto: ZUMAPRESS.com | La Nacion - picture allianceTrotz eines enorm starken Wachstums und einer günstigen Unternehmensbewertung ist Halozyme noch immer ein Nischenwert. Das dürfte nicht mehr lange... ► Artikel lesen | |
| AMYLYX PHARMACEUTICALS | 20,330 | +3,99 % | Biotech Stocks At 52-Week Highs - LH Rises With Genetic Testing Launch, DYN, SNDA, SLN, AMLX, | LONDON (dpa-AFX) - The following biotech stocks reached a 52-week high on July 27, 2026, driven by key catalysts including prospective clinical trial results, and the launch of new services.Dyne... ► Artikel lesen | |
| EDGEWISE THERAPEUTICS | 40,740 | +0,97 % | Servier completes the acquisition of Edgewise Therapeutics' Muscular Dystrophy Business | Acquisition supports Servier's strategic ambition in rare neurology with sevasemten, a late-stage investigational treatment for Becker and Duchenne muscular dystrophies. The acquired asset... ► Artikel lesen | |
| TANGO THERAPEUTICS | 27,090 | +1,65 % | Krebs-Blockbuster-Medikament: Revolution Medicines: Auch Europa will das Medikament so schnell wie möglich! | © Foto: KI-generiert mit DALL-ENach starken Studiendaten aus den USA will nach der FDA auch Europas Arzneimittelbehörde das Medikament so schnell wie möglich zulassen. Revolution Medicines wird immer... ► Artikel lesen |
ASCENTAGE PHARMA GROUP INTERNATIONAL ADR gehört der Branche Biotechnologie an. Mit einer aktuellen Kursveränderung von -0,400 (-2,65 %) liegt der Kurs bei 14,700 Euro.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und sowie Kurse und Daten von ARIVA.DE AG.
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu ASCENTAGE PHARMA GROUP INTERNATIONAL ADR finden Sie auf Wallstreet Online.